Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by SMARCB1 is part of a complex that relieves repressive chromatin structures, allowing the transcriptional machinery to access its targets more effectively. Additionally we are shipping SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Proteins (9) and SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Kits (4) and many more products for this protein.
Showing 10 out of 129 products:
Human Monoclonal SMARCB1 Primary Antibody for IHC (fro), IHC (p) - ABIN1109066
Bourdeaut, Fréneaux, Thuille, Lellouch-Tubiana, Nicolas, Couturier, Pierron, Sainte-Rose, Bergeron, Bouvier, Rialland, Laurence, Michon, Sastre-Garau, Delattre: hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. in The Journal of pathology 2007
Show all 5 references for ABIN1109066
Human Monoclonal SMARCB1 Primary Antibody for IF, WB - ABIN968741
Bruder, Dumanski, Kedra: The mouse ortholog of the human SMARCB1 gene encodes two splice forms. in Biochemical and biophysical research communications 1999
Show all 3 references for ABIN968741
Human Polyclonal SMARCB1 Primary Antibody for WB - ABIN658274
Bakshi, Hassan, Pratap, Lian, Montecino, van Wijnen, Stein, Imbalzano, Stein: The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes. in Journal of cellular physiology 2010
Show all 2 references for ABIN658274
Chicken Polyclonal SMARCB1 Primary Antibody for WB - ABIN2778302
Lazrek, Goffard, Schanen, Karquel, Bocket, Lion, Devaux, Hedouin, Gosset, Hober: Detection of hepatitis C virus antibodies and RNA among medicolegal autopsy cases in Northern France. in Diagnostic microbiology and infectious disease 2006
Show all 2 references for ABIN2778302
Human Monoclonal SMARCB1 Primary Antibody for IHC (p), ELISA - ABIN562912
Scurr, Pupo, Becker, Lai, Schrama, Haferkamp, Irvine, Scolyer, Mann, Becker, Kefford, Rizos: IGFBP7 is not required for B-RAF-induced melanocyte senescence. in Cell 2010
Human Polyclonal SMARCB1 Primary Antibody for ICC, IF - ABIN252863
Young, Jacks: Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. in Proceedings of the National Academy of Sciences of the United States of America 2010
Human Monoclonal SMARCB1 Primary Antibody for WB - ABIN393962
Wu, Ho, Lin, Lin: Rhabdoid papillary meningioma: a clinicopathologic case series study. in Neuropathology : official journal of the Japanese Society of Neuropathology 2011
Cow (Bovine) Polyclonal SMARCB1 Primary Antibody for IHC, WB - ABIN2778301
Mueller, Eum, Lass, Paulus, Sarkar, Bruck, von Deimling: No evidence of hSNF5/INI1 point mutations in choroid plexus papilloma. in Neuropathology and applied neurobiology 2004
Missense mutation in SMARCB1 gene is associated with Coffin-Siris phenotype, and schwannomatosis.
we report on a new Italian family with recurrence of SMARCB1 germ-line deletion in two siblings due to gonadal mosaicism
study describes a rare case of a novel nonsense mutation in SMARCB1 that causes schwannomatosis; first report of a SMARCB1 mutation in a schwannomatosis family exhibiting (unilateral) vestibular schwannoma; results constitute a significant finding given that SMARCB1 mutations can cause both conditions via a four-hit mechanism
Case Report: SMARCB1-deficient vulvar sarcoma expressing ERG (show ERG Antibodies) and FLI1 (show FLI1 Antibodies).
Macaca mulatta SMARCB1 showed 23 single nucleotide differences compared to the human ortholog and the amino acid sequence is 100% conserved between human and simian INI1.
Reduced expression of SMARCB1 immunoreactivity was found to be highly sensitive and specific for synovial sarcoma.
Mutations in INI1 that cause schwannomatosis target a hitherto unidentified N-terminal winged helix DNA binding domain that is also present in the BAF45a/PHF10 (show PHF10 Antibodies) subunit of the SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) complex.
Identification of SMARCB1 mutations adds to the growing literature regarding the role of epigenetic control mechanisms in melanoma progression and therapeutic resistance.
We report, for the first time, co-inactivation and frequent mutations of SMARCB1, SMARCA2 (show SMARCA2 Antibodies) and PBRM1 (show PBRM1 Antibodies) in MRTs.
a novel INI1(+) ATRT-like subtype among Taiwanese pediatric patients
The occurrence of intracranial rhabdoid tumours depends on control of Smarcb1 inactivation.
These results support recent findings regarding the effectivity of EGFR (show EGFR Antibodies) inhibitors in hindering the proliferation of human MRT cells and demonstrate that activation of EGFR (show EGFR Antibodies) signaling in Rhabdoid tumors is SMARCB1 dependent.
these findings uncover a novel role for Snf5 in oligodendrocyte generation and survival, and they offer evidence of the first genetically engineered mouse model for AT/RT in the CNS.
This study show here that loss of Smarcb1 and Smarca4 (show SMARCA4 Antibodies) leads to severe proliferation deficits of granule neuron precursors and a hypoplastic cerebellum.
results show that Smarcb1 is required for transcriptional activation of Igfbp7 (show IGFBP7 Antibodies) and show that re-introduction of Igfbp7 (show IGFBP7 Antibodies) alone can hinder tumor development; results define a novel mechanism for Smarcb1-mediated tumorigenesis
We find that inactivation of either Brg1 (show SMARCA4 Antibodies) or Smarcb1 leads to disruptions of specific nucleosome patterning combined with a loss of overall nucleosome occupancy at a large number of promoters, regardless of their association with CpG islands.
SNF5 is a key mediator of Hedgehog (show SHH Antibodies) signaling and that aberrant activation of GLI1 (show GLI1 Antibodies) is a previously undescribed targetable mechanism contributing to the growth of malignant rhabdoid tumor cells.
Loss of the SNF5 tumor suppressor leads to elevated expression of the Polycomb (show CBX2 Antibodies) gene EZH2 (show EZH2 Antibodies).
SNF5 knockdown inhibits p53 (show TP53 Antibodies) translation by eIF4E (show EIF4E Antibodies) and replacement of eIF4E (show EIF4E Antibodies) in SNF5 knockdown cells restores p53 (show TP53 Antibodies) expression and cell survival
The loss of this protein, a core subunit of SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies), results in highly penetrant cancer predisposition with 100% of mice developing mature CD8 (show CD8A Antibodies)(+)T cell lymphoma or rare rhabdoid tumors with a median onset of only 11 weeks.
The protein encoded by this gene is part of a complex that relieves repressive chromatin structures, allowing the transcriptional machinery to access its targets more effectively. The encoded nuclear protein may also bind to and enhance the DNA joining activity of HIV-1 integrase. This gene has been found to be a tumor suppressor, and mutations in it have been associated with malignant rhabdoid tumors. Two transcript variants encoding different isoforms have been found for this gene.
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1
, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1
, matrix metalloproteinase 11 (stromelysin 3)
, BRG1-associated factor 47
, SNF5 homolog
, integrase interactor 1 protein
, malignant rhabdoid tumor suppressor
, sucrose nonfermenting, yeast, homolog-like 1
, SWI/SNF-related matrix associated protein